Turner syndrome and pregnancy
Clinical practice recommendations

Mission
Following the death by acute aortic dissection of two women with Turner syndrome who were pregnant following egg donation, the Director General of the Agence de la biomédecine sent a letter on 2 July 2008 to the President of the French National College of Gynaecologists and Obstetricians (CNGOF) requesting the College’s expertise in reviewing point by point the cases and risk factors and in determining whether there are grounds to propose measures complementary to the recommendations made by the Haute autorité de santé (HAS) in 2008 in terms of indication and monitoring of patients, with a view to improving healthcare safety.

Working group

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Speciality</th>
<th>Name and email address</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNGOF</td>
<td>President of the College</td>
<td>Jacques Lansac <a href="mailto:jiacques.lansac@wanadoo.fr">jiacques.lansac@wanadoo.fr</a></td>
<td></td>
</tr>
<tr>
<td>CHU Bichat</td>
<td>Cardiologist (adults)</td>
<td>Guillaume Jondeau <a href="mailto:guillaume.jondeau@bch.aphp.fr">guillaume.jondeau@bch.aphp.fr</a></td>
<td>Appointed by the French Cardiology Society</td>
</tr>
<tr>
<td>CHU Cochin</td>
<td>Cardiologist</td>
<td>Laure Cabanes <a href="mailto:laure.cabanes@cch.aphp.fr">laure.cabanes@cch.aphp.fr</a></td>
<td></td>
</tr>
<tr>
<td>CHU Cochin</td>
<td>Medical technologist</td>
<td>Céline Chalas <a href="mailto:celine.chalas@cch.aphp.fr">celine.chalas@cch.aphp.fr</a></td>
<td></td>
</tr>
<tr>
<td>Hôpital Foch</td>
<td>Anaesthetist</td>
<td>Marie-Louise Felten <a href="mailto:ml.felten@hopital-foch.org">ml.felten@hopital-foch.org</a></td>
<td>Appointed by the French Anaesthesia and Intensive Care Society</td>
</tr>
<tr>
<td>Hôpital Foch</td>
<td>Radiologist</td>
<td>Virginia Gaxotte <a href="mailto:v.gaxotte@hopital-foch.org">v.gaxotte@hopital-foch.org</a></td>
<td></td>
</tr>
<tr>
<td>Hôpital Foch</td>
<td>Heart surgeon</td>
<td>Emmanuel Lansac <a href="mailto:e.lansac@hopital-foch.org">e.lansac@hopital-foch.org</a></td>
<td></td>
</tr>
<tr>
<td>CHU Strasbourg</td>
<td>Gynaecologist-obstetrician</td>
<td>Jeanine Ohl <a href="mailto:jeanine.OHL@sihcus.fr">jeanine.OHL@sihcus.fr</a></td>
<td>Reference centre for rare endocrine disorders of growth</td>
</tr>
<tr>
<td>CHU St Antoine</td>
<td>Endocrinologist</td>
<td>Sophie Christin Maitre <a href="mailto:sophie.christin-maitre@sat.aphp.fr">sophie.christin-maitre@sat.aphp.fr</a></td>
<td></td>
</tr>
<tr>
<td>CHU St Antoine</td>
<td>Endocrinologist</td>
<td>Bruno Donadille bruno.donadille @sat.aphp.fr</td>
<td>Reference centre for rare endocrine disorders of growth</td>
</tr>
<tr>
<td>CHU Poitiers</td>
<td>Gynaecologist-obstetrician</td>
<td>Titia N’Diaye <a href="mailto:mamegormack@yahoo.fr">mamegormack@yahoo.fr</a></td>
<td></td>
</tr>
<tr>
<td>CHU Avicenne</td>
<td>Hepatologist</td>
<td>Dominique Roulot <a href="mailto:dominique.roulot@avc.aphp.fr">dominique.roulot@avc.aphp.fr</a></td>
<td></td>
</tr>
<tr>
<td>CHU Robert Debré</td>
<td>Paediatrician</td>
<td>Delphine Zénaty <a href="mailto:delphine.zenaty@rdb.aphp.fr">delphine.zenaty@rdb.aphp.fr</a></td>
<td>Reference centre for rare endocrine disorders of growth</td>
</tr>
<tr>
<td>Agence de la biomédecine Direction médicale et scientifique</td>
<td>Public health/safety-quality</td>
<td>Ann Pariente-Khayat <a href="mailto:ann.pariente-khayat@biomedecine.fr">ann.pariente-khayat@biomedecine.fr</a> Francois Thepot <a href="mailto:francois.thepot@biomedecine.fr">francois.thepot@biomedecine.fr</a></td>
<td></td>
</tr>
</tbody>
</table>
Introduction

Turner syndrome is associated with monosomy X (45 X and mosaic) in 50% of cases and with rearrangements of the short arms of chromosome X in the remaining 50%. Along with short stature, primary amenorrhoea is the cardinal sign of Turner syndrome. Spontaneous pregnancies are very rare (2%) in women with Turner syndrome [1], and primarily occur when the syndrome is associated with an X anomaly (number or structure) and mosaicism. For the vast majority of such women, being an egg recipient is the only way to become pregnant (Appendix VII lists the accredited centres).

These pregnancies carry particular risks inasmuch as 5 to 50% of women with Turner syndrome have a cardiovascular malformation [2, 3, 4, 5]; coarctation of the aorta (10% of cases), bicuspid aortic valve (25% of cases) [6]. The most serious maternal complications are therefore cardiovascular, such as worsening of pre-existing hypertension or aortic dissection which, as in Marfan syndrome [19], may be life-threatening [7]. An estimated 2% of women with Turner syndrome are at risk of death caused by aortic dissection or rupture, a rate 100 times that of women in the general population [17]. The risk factors for dissection are bicuspid aortic valve, coarctation and hypertension [7, 8]. In reported cases of dissection, aortic diameter measured by magnetic resonance imaging (MRI) at the right pulmonary artery was above 25 mm/m² or 35 mm on average 3 years before the dissection [17]. Values well above these were reported in the two French cases. The risk of dissection during pregnancy is unclear, but all literature cases to date suggest it may be about 10%, bearing in mind the bias of such retrospective studies. This risk is increased at the end of pregnancy since 50% of aortic dissections reported in the literature occur in the third trimester [8] or post-partum.

A review of the literature between 1961 and 2006 revealed 85 cases of aortic dissection in women with Turner syndrome. In the 7 cases of aortic dissection reported after assisted reproductive technologies (ART), 6 patients died [9, 10, 11]. Severe hepatic steatosis or cholestasis, and pregnancy-induced hypertension have been reported [12, 13, 14]. In 2008 the HAS published a national protocol for diagnosis and care of Turner syndrome [15] that includes a section on pregnancy, which needs to be updated in view of the possibility of pregnancy through egg donation and recent publications on the complications of Turner syndrome during pregnancy [16, 18, 20-24]. Given the rarity of pregnancy in Turner syndrome patients, the literature data are of a low level of proof and the following recommendations are essentially based on expert opinions.

Peer review group

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Speciality</th>
<th>Name and email address</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHU Robert Debré</td>
<td>Paediatric endocrinologist</td>
<td>Juliane Léger <a href="mailto:juliane.leger@rdb.aphp.fr">juliane.leger@rdb.aphp.fr</a></td>
<td>Reference centre for rare endocrine disorders of growth</td>
</tr>
<tr>
<td>CHU Beaugon</td>
<td>Gynaecologist-obstetrician</td>
<td>Dominique Luon <a href="mailto:dluton@free.fr">dluton@free.fr</a></td>
<td>General Secretary of CNGOF</td>
</tr>
<tr>
<td>CHU de Lille</td>
<td>Heart surgeon</td>
<td>Alain Prat <a href="mailto:aprat@chru-lille.fr">aprat@chru-lille.fr</a></td>
<td>Appointed by the Chest and Cardiovascular Surgery Society</td>
</tr>
<tr>
<td>CHU Créteil</td>
<td>Cardiologist</td>
<td>Pascal Gueret <a href="mailto:pascal.gueret@hmn.aphp.fr">pascal.gueret@hmn.aphp.fr</a>. <a href="mailto:contact@cardio-sfc.org">contact@cardio-sfc.org</a></td>
<td>President of the French Cardiology Society</td>
</tr>
<tr>
<td>CHU Tenon</td>
<td>Anaesthetist</td>
<td>Francis Bonnet francis.bonnet @tnn.aphp.fr</td>
<td>Copyeditor appointed by the French Society of Anaesthesia and Intensive Care</td>
</tr>
<tr>
<td>CHU Bichat</td>
<td>Cardiologist</td>
<td>Delphine Detaint <a href="mailto:delphine.detaint@bch.aphp.fr">delphine.detaint@bch.aphp.fr</a></td>
<td>Reference centre for Marfan syndrome and related diseases</td>
</tr>
<tr>
<td>HEGP</td>
<td>Cardiologist</td>
<td>Laurence Iserin <a href="mailto:laurence.iserin@egp.aphp.fr">laurence.iserin@egp.aphp.fr</a></td>
<td></td>
</tr>
</tbody>
</table>
Work-up before pregnancy

A work-up should be done in every patient who wishes to become pregnant, whatever her karyotype (mosaic or 45 X), and whether pregnancy is sought naturally (if ovarian function is conserved, as it generally is in patients with a mosaic karyotype) or through third-party reproduction (egg donation). The work-up should be multidisciplinary and involve specialists in cardiology, endocrinology, nephrology, hepatology, and so forth.

General examination
Weight, height, body mass index.

Cardiovascular examination
Hypertension, bicuspid aortic valve, aortic dilatation and coarctation are aortic dissection risk factors in women with Turner syndrome.

Blood pressure: measured at rest, possibly completed by ambulatory blood pressure monitoring. If hypertension is found, a renal cause is sought, using Doppler ultrasonography of the renal arteries (see below).

Two-dimensional transthoracic ultrasound with colour Doppler imaging, left parasternal long-axis view during end-diastole (recommendations of the cardiologists of the HAS working group on Turner syndrome; normal values of Roman et al. related to body surface area [25]), is used to search for aortic malformations (bicuspid aortic valve: 25% of patients, coarctation: 10%, anomalies of the structure of the aorta) and anomalies of venous return, to screen for acquired aortic disease (aneurysm, dilatation), and during follow-up. The four diameters characteristic of the aortic root are measured (the largest is used) and screening for bicuspid aortic valve is performed. These ultrasound examinations should be done by an ultrasonographer-cardiologist according to the standardised methodology proposed in Appendix I.

Magnetic resonance angiography of the heart and aorta [18-24] is mandatory. It has the advantage of not exposing the patient to radiation and can be used to:
  - analyse the whole of the thoracic and abdominal aorta;
  - measure the four diameters of the aortic root;
  - screen for or confirm coarctation, bicuspid aortic valve;
  - do successive comparative analyses;
  - observe the renal arteries if the acquisition area allows.
The aortic diameter indexed for body surface area is measured by MRI at the right pulmonary artery. The 50th percentile is 17 mm/m² in patients with Turner syndrome and the 95th percentile is 20 mm/m² [17]. An indexed aortic diameter greater than or equal to 25 mm/m² or above 35 mm should be considered to indicate a dilated aorta at risk of dissection.
Appendix II describes a protocol for MRI of the ascending aorta.
When MRI cannot be performed (pacemaker, defibrillator, catheter or other equipment), computed tomography of the aorta should be considered.

Endocrine tests
Blood tests:
  - thyroid stimulating hormone, free thyroxine, antithyroid antibodies (anti-TPO);
  - fasting blood glucose, and HbA1c in cases of diabetes.
Possibly, plasma lipid profile to check for dyslipidaemia, other vascular risk factors.

Liver function tests
  - blood tests: aspartate transaminase, alanine transaminase, gamma glutamyl transpeptidase and alkaline phosphatase;
  - liver ultrasound when laboratory tests six months apart show anomalies: notably testing for portal hypertension.
If there are anomalies, specialist advice should be sought regarding aetiology.

Gynaecological evaluation
  - a gynaecological examination;
  - smear test if the last one was over two years ago;
  - pelvic ultrasound with Doppler imaging of the uterine arteries, measurement of the uterus and of endometrial thickness, check for uterine malformation;
  - if malformation suspected, 3D ultrasound and hysteroscopy.
Kidney function tests
- renal ultrasound to check for:
  - malformation (30% of cases): horseshoe kidney, ectopic kidney, renal agenesis, duplication
  - hydronephrosis
  - cause of secondary hypertension (stenosis of renal arteries);
- laboratory tests in cases of hypertension or renal anomaly: blood urea nitrogen, blood creatinine, blood electrolytes, urine electrolytes;
- urine culture to check for urinary infection.

Contraindications to pregnancy

Cardiovascular
Pregnancy is contraindicated if there is:
- a history of aortic surgery;
- a history of aortic dissection;
- aortic dilatation: the largest aortic diameter is above 25 mm/m² or 35 mm. This is an extrapolation of measurements made at the tubular aorta [18];
- coarctation of the aorta;
- hypertension uncontrolled despite treatment.
Even if surgery of the valves or aorta has been performed, the patient is still at risk of aortic dissection in pregnancy, which remains contraindicated. Isolated bicuspid aortic valve (without aortic dilatation) is not a contraindication to pregnancy, but is a risk factor.

Hepatic
Portal hypertension with oesophageal varices.

Information for the patient
If there are no contraindications and if a pregnancy is envisaged, the gynaecologist-obstetrician, cardiologist and endocrinologist should work together to inform the patient and if possible the couple, who will be given a written document (Appendix III).
The patient and where possible the couple should be informed that:
- there is an increased risk of miscarriage and chromosomal abnormalities in spontaneous pregnancy (without egg donation). An interview with a doctor specialised in genetics should be proposed, along with the possibility of prenatal diagnosis;
- pregnancy carries a high risk of potentially life-threatening (mother and child) cardiovascular complications (hypertension, pre-eclampsia, aortic dissection), and metabolic complications (diabetes);
- in cases of egg donation only one embryo will be transferred to avoid multiple pregnancies;
- there is an increased risk of caesarean delivery because of a small pelvis and possible medical complications (85% of births are caesarean);
- the patient must be followed up by a specialised multidisciplinary team that includes at least a gynaecologist-obstetrician, a cardiologist and an anaesthetist. The anaesthetist will study specific problems concerning control of blood pressure and blood glucose during the peripartum period and regarding the airways because of a greater likelihood of difficult intubation. Spinal examination is also necessary because of the possibility of spinal anaesthesia or epidural anaesthesia. Vaginal delivery or caesarean delivery must take place in a medical facility staffed by a team of cardiologists and a heart surgery team;
- risks for the unborn child because of obstetrical or cardiovascular complications: prematurity, intrauterine growth retardation requiring neonatal intensive care.
When there is a combination of diseases or failure to observe medical instructions, the multidisciplinary team has the right to refuse ART with egg donation, or in cases of persistent ovarian dysfunction the team can formally advise against pregnancy, after having informed the patient.

Conditions for medical acceptance of pregnancy

Cardiovascular
If the aortic diameter is less than 25 mm/m² and 35 mm and there is no associated coarctation:

* In the legal sense of the term, in France, such a facility could include several hospitals (examples: the public hospitals of major cities, like Paris, Lyon or Strasbourg)
- the pregnancy can be authorised;
- pending egg donation, ultrasonography is repeated yearly by the same sonographer. If aortic dilatation increases by 10% or more, this must be confirmed using a second imaging technique (MRI, computed tomography or transoesophageal ultrasound). If confirmed, progression of aortic dilatation becomes a contraindication to pregnancy.

**Liver function tests**
Pending egg donation, the liver function tests are repeated every year if the initial findings were normal or on the advice of a hepatologist.

**Recommendations in the case of ART**
In ART with egg donation (Appendix VII lists centres accredited for egg donation), it is strongly recommended to transfer a single embryo to avoid multiple pregnancies. When embryo transfer is done, the patient must be reminded of the risks of pregnancy and the need for close follow-up.

If there is an incident or adverse event, it must be reported to the Agence de la biomédecine by the local correspondent of the health watchdog for ART, or by any health professional who knows of the occurrence of such an incident or adverse event (Journal officiel no. 0301 of 27 December 2008, page 20184, text no. 69, NOR: SJSP0830456A). Appendix V outlines the reporting procedure.

**Recommendations for pregnancy follow-up**
Pregnancy follow-up should be multidisciplinary and concerted.

**Cardiovascular monitoring**

Echocardiography (Appendix I):
- at the end of the first and second trimesters;
- every month during the third trimester;
- an increase in aortic diameter greater than or equal to 10% between two examinations should be confirmed by MRI (Appendix II).

In the case of acute dissection of the aortic root during pregnancy:
Medical management will depend on the stage of pregnancy:
- before 25 weeks of gestation, emergency aortic root surgery with extracorporeal circulation, foetus in utero, with cardiotocography. The risk of maternal and/or foetal death is high;
- after 25 weeks of gestation, emergency caesarean section, immediately followed by aortic root surgery.

If the aortic diameter becomes greater than 25 mm/m² or 35 mm or if it increases by >10% between two examinations or with respect to the reference examination before the pregnancy:
- hospitalisation in a facility with a medical-surgical cardiology team and a maternity centre with a department of neonatology and/or neonatal intensive care if delivery before 32 weeks of gestation;
- cardiological and surgical advice is sought in a reference centre (Appendix IV)
- acceleration of foetal lung maturation if delivery is between 25 and 34 weeks of gestation;
- planned caesarean section.

If the aortic diameter remains unchanged and below 25 mm/m² and 35 mm:
Delivery can take place in a facility* staffed by a team of cardiologists and a heart surgery team. Caesarean section is necessary in 85% of cases because of narrowness of the pelvis. The timing of the caesarean after 34 weeks of gestation will depend on the mother’s cardiovascular status. Vaginal delivery with close blood pressure monitoring can be envisaged if there is no foetal-pelvic disproportion or associated disease. Assisted delivery (vacuum extractor or forceps) is recommended.

**Hypertension**
Hypertension should be treated with a beta-blocker and treatment efficacy checked by ambulatory blood pressure monitoring. Even if there is no hypertension, beta-blocker treatment during pregnancy can be considered.

---

* In the legal sense of the term, in France, such a facility could include several hospitals (examples: the public hospitals of major cities, like Paris, Lyon or Strasbourg)
Liver function tests
Liver function tests are only needed in the event of a clinical sign, such as pruritus or jaundice. In cases of cholestasis, management is identical to that of a pregnant woman without Turner syndrome.

Screening for gestational diabetes
The O’Sullivan test is done at 24 weeks of gestation.

Kidney function tests
Blood creatinine level is determined every month in cases of renal malformation.

Postnatal follow-up

Cardiovascular
As cardiovascular risk persists after delivery, there should be ultrasound monitoring of the aortic root diameters between 5 and 8 days after the delivery by a specialised ultrasonographer and according to the protocol in Appendix I.

Hepatic
No liver function tests in the absence of previous abnormal laboratory findings or clinical manifestations.

Obstetrical
As for any woman who has given birth vaginally or by caesarean section, at 6 weeks post-partum.

Examination of the infant
For pregnancy not involving egg donation, the paediatric examination is used to check for chromosomal abnormalities: Turner syndrome for a girl, trisomy 21.
For pregnancy after egg donation, the paediatric examination does not include any special tests.

Reporting to the Turner Syndrome Registry
Any pregnancy with or without egg donation in a woman with Turner syndrome must be reported to the Turner Syndrome Registry at the email address: crmerc.turner@rdb.aphp.fr. The reporting form is given in Appendix VI.

References
## Appendix I – Transthoracic cardiac ultrasound

### Dilated aorta: > 20 mm/m² of body surface area

### High risk of dissection: > 25 mm/m² of body surface area

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Before pregnancy</th>
<th>1st trimester</th>
<th>2nd trimester</th>
<th>3rd trimester</th>
<th>15 days after delivery</th>
<th>8 weeks after delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td></td>
<td>1st month</td>
<td>2nd month</td>
<td>3rd month</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter of aortic annulus (mm/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter at sinus of Valsalva (mm/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter at sinotubular junction (mm/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcoronary diameter of ascending aorta (mm/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aortic regurgitation (grade 0, I, II, III, IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicuspid aortic valve</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coarctation of the aorta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix II - Magnetic resonance imaging of the ascending aorta

Magnetic resonance system (1.5 Tesla)
Antenna in phase network: cardiac or thoracic, preferred to the machine’s antenna.
Whole magnetic resonance imaging (MRI) of the aorta recorded on a CD-ROM.

EXAMINATION BEFORE PREGNANCY

Morphology of the aorta
- Black blood technique in axial thoracic sections: T1- or T2-weighted fast spin-echo sequence, synchronised with the ECG

Magnetic resonance angiography
- Gadolinium-enhanced three-dimensional magnetic resonance angiography (gadolinium 0.2 mmol/kg)
- Acquisition in the coronal plane with centring between the ascending and descending aortas
- Coverage of renal arteries if possible (patients of short stature): look for stenosis
- Multiplanar reconstructions in the plane perpendicular to the aortic axis centred on:
  1: the aortic root
  2: the sinus of Valsalva
  3: the sinotubular junction
  4: the tubular aorta
  with measurement of the aortic diameters at these different levels
- Volume rendering of the thoracic aorta

Additional sequences
- Steady-state free precession sequences centred on the aortic valve (axial sections +/- phase-contrast MRI and velocimetry) to screen for a bicuspid aortic valve.
In coarctation of the aorta: velocimetry and phase-contrast MRI centred on the coarctation to check for a trans-stenotic pressure gradient.

DURING PREGNANCY

Morphology of the aorta
- Black blood technique in axial thoracic sections: T1- or T2-weighted fast spin-echo sequence, synchronised with the ECG
- Steady-state free precession sequences (true fast imaging with steady-state precession [true FISP] – fast imaging employing steady-state acquisition [FIESTA] – balanced turbo field echo [b-TFE]) centred on the ascending aorta (coronal plane, oblique parasagittal plane, plane perpendicular to the aortic valve…)
Measurement of aortic diameters at the:
  1: aortic root
  2: sinus of Valsalva
  3: sinotubular junction
  4: tubular aorta
Appendix III - Information document for the patient and her partner

Madam, Sir,

Madam, as you know, you have a chromosomal abnormality called Turner syndrome, which is characterised by the partial or complete absence of one of the two X chromosomes normally observed.

Spontaneous pregnancies in cases of preserved ovarian function are rare (2%) and carry an increased risk of miscarriage and chromosomal abnormalities. You are advised to agree to an appointment with a doctor specialised in genetics to determine the risk of transmission to the child of a genetic abnormality, and to discuss the possibility of prenatal diagnosis.

In most cases of Turner syndrome, being an egg recipient is the only way to become pregnant.

Whether the pregnancy is spontaneous or medically assisted through egg donation, it is at high risk of complications:
- cardiovascular (hypertension, dilatation even rupture of the aorta): life-threatening for both mother and child;
- metabolic: diabetes;
- hepatic: bile retention;
- obstetrical: hypertension, pre-eclampsia. In 85% of cases, caesarean delivery is necessary, notably because of a narrow pelvis.

Before considering pregnancy, a review by a specialised medical team is essential. This review involves:
- a consultation with a cardiologist to measure blood pressure and for ultrasound examination or magnetic resonance imaging (MRI) of the heart;
- a consultation with an endocrinologist to test for diabetes, thyroid gland disease, liver disease and kidney disease;
- a consultation with a gynaecologist-obstetrician to assess the condition of the womb and to measure the pelvis. It may be necessary to examine the pelvis by ultrasound or MRI or both.

After this medical review, the specialised multidisciplinary team may formally advise against pregnancy, particularly if you have had surgery on the aorta or if testing has revealed hypertension or if ultrasound examination of the heart gives abnormal findings.

If pregnancy is not contraindicated and you are awaiting egg donation, an annual appointment with the cardiologist will be necessary. Liver function tests will also be done every year.

With egg donation or other techniques of ART procreation, you will receive a single embryo to avoid a multiple pregnancy, which would increase the risk of complications.

During pregnancy, apart from the usual follow-up by the gynaecologist-obstetrician, it will be necessary to see the cardiologist for further ultrasound scans at the end of the first and second trimesters, and also every month of the last trimester of the pregnancy.

If during pregnancy the aorta dilates by more than 10% compared with the measurement at the start of pregnancy, it may be necessary to deliver your baby by caesarean before term and to operate on your aorta. If hypertension occurs, treatment may be necessary. There may also be a liver complication that causes itching and jaundice and which will require treatment or even premature delivery of the baby.

If the pregnancy goes well and reaches term, the delivery should take place in a centre with, in addition to a maternity department and a paediatric department, a team of cardiologists and heart surgeons, as emergency cardiac intervention may be necessary. The route of delivery will be discussed with the obstetrician, but most often (available data suggest 85% of cases) it will be necessary to perform a caesarean section.

After the delivery, cardiac monitoring by the same team will be needed, and ultrasound scans should be done 2 and 8 weeks after the birth, and then every year.

Yours is a high-risk pregnancy, particularly because of the possibility of dilation or even rupture of the aorta, which requires emergency cardiac intervention. In the absence of suitable care and multidisciplinary monitoring by a specialised team, complications may be life-threatening for you and your child. On the basis of available information, notably after recommendations from the team in charge of your treatment, it is therefore necessary, with your partner and the team, to weigh up the difficulties and risks of such a pregnancy and of possible alternatives. The team is there to help you make a decision. If you decide to have a child, your close collaboration is essential if the pregnancy is to be completed successfully.
**Appendix IV – Reference centres and competence centres for management of pregnancy in women with Turner syndrome**

### Reference endocrinology centres

<table>
<thead>
<tr>
<th>Reference centres</th>
<th>City</th>
<th>Hôpital</th>
<th>Names of coordinators at each site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare endocrine disorders or growth</td>
<td>Paris</td>
<td>Robert Debré</td>
<td>Prof Juliane LEGER - <a href="mailto:juliane.leger@rdb.aphp.fr">juliane.leger@rdb.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prof Jean-Claude CAREL - <a href="mailto:jean-claude.carel@rdb.aphp.fr">jean-claude.carel@rdb.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necker</td>
<td>Prof Michel POLAK - <a href="mailto:michel.polak@nck.aphp.fr">michel.polak@nck.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bicêtre</td>
<td>Prof Philippe CHANSON - <a href="mailto:philippe.chanson@bct.aphp.fr">philippe.chanson@bct.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prof Jacques YOUNG - <a href="mailto:jacques.young@bct.aphp.fr">jacques.young@bct.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>La Pitié</td>
<td>Prof Frédérique KUTTENN - <a href="mailto:frederique.kutten@psl.aphp.fr">frederique.kutten@psl.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salpêtrière</td>
<td>Prof Philippe TOURAIN - <a href="mailto:philippe.touraine@psl.aphp.fr">philippe.touraine@psl.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>St Antoine</td>
<td>Prof Philippe BOUCHARD - <a href="mailto:philippe.bouchard@sat.aphp.fr">philippe.bouchard@sat.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prof Sophie CHRISTIN MAITRE - <a href="mailto:sophie.christin-maitre@sat.aphp.fr">sophie.christin-maitre@sat.aphp.fr</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Armand Trousseau</td>
<td>Prof Yves LEBOUC - <a href="mailto:yves.lebouc@trs.aphp.fr">yves.lebouc@trs.aphp.fr</a></td>
</tr>
</tbody>
</table>

### Endocrinology knowledge centres

<table>
<thead>
<tr>
<th>City</th>
<th>Coordinator</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strasbourg</td>
<td>Dr Sylvie SOSKIN</td>
<td><a href="mailto:sylvie.soskin@chru-strasbourg.fr">sylvie.soskin@chru-strasbourg.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Nathalie JEANDIDIER</td>
<td><a href="mailto:nathalie.jeandidier@chru-strasbourg.fr">nathalie.jeandidier@chru-strasbourg.fr</a></td>
</tr>
<tr>
<td>Bordeaux</td>
<td>Dr Pascal BARAT</td>
<td><a href="mailto:pascal.barat@chu-bordeaux.fr">pascal.barat@chu-bordeaux.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Antoine TABARIN</td>
<td><a href="mailto:antoine.tabarin@chu-bordeaux.fr">antoine.tabarin@chu-bordeaux.fr</a></td>
</tr>
<tr>
<td>Clermont-Ferrand</td>
<td>Dr Hélène CARLA</td>
<td><a href="mailto:hcarla@chu-clermontferrand.fr">hcarla@chu-clermontferrand.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Igor TAUVERON</td>
<td><a href="mailto:tauveron@chu-clermontferrand.fr">tauveron@chu-clermontferrand.fr</a></td>
</tr>
<tr>
<td>Dijon</td>
<td>Dr Frédéric HUET</td>
<td><a href="mailto:frederic.huet@chu-dijon.fr">frederic.huet@chu-dijon.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Bruno BERGES</td>
<td><a href="mailto:bruno.berges@chu-dijon.fr">bruno.berges@chu-dijon.fr</a></td>
</tr>
<tr>
<td>Rennes</td>
<td>Dr Sylvie NIVOT-ADAMIACK</td>
<td><a href="mailto:sylvie.nivot-adamiak@chu-rennes.fr">sylvie.nivot-adamiak@chu-rennes.fr</a></td>
</tr>
<tr>
<td>Brest</td>
<td>Prof Véronique KERLAN</td>
<td><a href="mailto:veronique.kerlan@univ-brest.fr">veronique.kerlan@univ-brest.fr</a></td>
</tr>
<tr>
<td>Tours</td>
<td>Dr François DESPRET</td>
<td><a href="mailto:despret@med.univ-tours.fr">despret@med.univ-tours.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Pierre LECOMTE</td>
<td><a href="mailto:lecomte@med.univ-tours.fr">lecomte@med.univ-tours.fr</a></td>
</tr>
<tr>
<td>Reims</td>
<td>Dr Véronique SULMONT</td>
<td><a href="mailto:vsulmont@chu-reims.fr">vsulmont@chu-reims.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Brigitte DELEMER</td>
<td><a href="mailto:bdelemert@chu-reims.fr">bdelemert@chu-reims.fr</a></td>
</tr>
<tr>
<td>Besançon</td>
<td>Dr Anne-Marie BERTRAND</td>
<td><a href="mailto:bertrand.anne-marie@wanadoo.fr">bertrand.anne-marie@wanadoo.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Alfred PENFORSNI</td>
<td><a href="mailto:alfred.penfornis@univ-fcomte.fr">alfred.penfornis@univ-fcomte.fr</a></td>
</tr>
<tr>
<td>Montpellier</td>
<td>Prof Charles SULTAN</td>
<td><a href="mailto:c-sultan@chu-montpellier.fr">c-sultan@chu-montpellier.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Jacques BRINGER</td>
<td><a href="mailto:j-bringer@chu-montpellier.fr">j-bringer@chu-montpellier.fr</a></td>
</tr>
<tr>
<td>Nancy</td>
<td>Dr Bruno LEHEUP</td>
<td><a href="mailto:b.leheup@chu-nancy.fr">b.leheup@chu-nancy.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Georges WERYHA</td>
<td><a href="mailto:g.weryha@chu-nancy.fr">g.weryha@chu-nancy.fr</a></td>
</tr>
<tr>
<td>Lille</td>
<td>Dr Jacques WEILL</td>
<td><a href="mailto:jweill@chru-lille.fr">jweill@chru-lille.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Jean-Louis WEMEAU</td>
<td><a href="mailto:j-l-wemelau@chru-lille.fr">j-l-wemelau@chru-lille.fr</a></td>
</tr>
<tr>
<td>Nantes</td>
<td>Dr Sabine BARON</td>
<td><a href="mailto:sabine.baron@chu-nantes.fr">sabine.baron@chu-nantes.fr</a></td>
</tr>
<tr>
<td></td>
<td>Prof Bernard CHARBONNEL</td>
<td><a href="mailto:bernard.charbonnel@univ-nantes.fr">bernard.charbonnel@univ-nantes.fr</a></td>
</tr>
<tr>
<td>Amiens</td>
<td>Dr Hélène BONY TRIFUNOVIC</td>
<td><a href="mailto:bony.helene@chu-amiens.fr">bony.helene@chu-amiens.fr</a></td>
</tr>
<tr>
<td></td>
<td>Dr Rachel DESAILLOUD</td>
<td><a href="mailto:desailloud.rachel@chu-amiens.fr">desailloud.rachel@chu-amiens.fr</a></td>
</tr>
<tr>
<td>Nice</td>
<td>Dr Kathy WAGNER MAHLER</td>
<td><a href="mailto:wagner.k@chu-nice.fr">wagner.k@chu-nice.fr</a></td>
</tr>
<tr>
<td></td>
<td>Dr Elisabeth BAECHLER</td>
<td><a href="mailto:elisabeth.baechler@lerval.com">elisabeth.baechler@lerval.com</a></td>
</tr>
<tr>
<td></td>
<td>Prof Patrick PENICHEL</td>
<td><a href="mailto:fenichel.p@chu-nice.fr">fenichel.p@chu-nice.fr</a></td>
</tr>
<tr>
<td>St Etienne</td>
<td>Dr Odile RICHARD</td>
<td><a href="mailto:odile.richard@chu-st-etienne.fr">odile.richard@chu-st-etienne.fr</a></td>
</tr>
<tr>
<td>Grenoble</td>
<td>Prof Olivier CHABRE</td>
<td><a href="mailto:olivierchabre@chu-grenoble.fr">olivierchabre@chu-grenoble.fr</a></td>
</tr>
</tbody>
</table>
Reference centres and knowledge centres for Marfan syndrome and related diseases with links to a centre specialised in development (the correspondents are coordinators in touch with cardiologists)

### Reference centres

<table>
<thead>
<tr>
<th>Location</th>
<th>Name</th>
<th>Address</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paris 14th district</td>
<td>Dr Daniel Czitrom</td>
<td>Institut mutualiste Montsouris, Service de cardiologie du Pr Laborde, 42 boulevard Jourdan, 75014 Paris</td>
<td><a href="mailto:daniel.czitrom@imm.fr">daniel.czitrom@imm.fr</a></td>
</tr>
<tr>
<td>Paris 15th district</td>
<td>Dr Laurence Iserin</td>
<td>Hôpital européen Georges Pompidou, Service de cardiologie du Pr Le Heuzet, 22 rue Leblanc, 75015 Paris</td>
<td><a href="mailto:laurence.iserin@egp.aphp.fr">laurence.iserin@egp.aphp.fr</a></td>
</tr>
<tr>
<td>Paris 18th district</td>
<td>Dr Guillaume Jondeau</td>
<td>Centre de référence pour le syndrome de Marfan et apparentés, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris</td>
<td>Tel: 01 40 25 68 11 <a href="mailto:Consultation.marfan@bch.aphp.fr">Consultation.marfan@bch.aphp.fr</a> <a href="http://www.marfan.fr">www.marfan.fr</a></td>
</tr>
</tbody>
</table>

### Knowledge centres

<table>
<thead>
<tr>
<th>Location</th>
<th>Name</th>
<th>Address</th>
<th>Email</th>
<th>Phone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lyon</td>
<td>Prof Henri Plauchu</td>
<td>Hôtel Dieu, 69228 Lyon 02</td>
<td>Tel: 04 72 41 32 93 <a href="mailto:henri.plauchu@chu-lyon.fr">henri.plauchu@chu-lyon.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dijon</td>
<td>Prof Laurence Faivre</td>
<td>Hôpital d'enfants, 10 boulevard Maréchal de Lattre de Tassigny, 21034 Dijon</td>
<td>Tel: 03 80 29 33 00 <a href="mailto:laurence.faivre@chu-dijon.fr">laurence.faivre@chu-dijon.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marseille</td>
<td>Dr Patrick Collignon</td>
<td>Hôpital de la Timone, 13385 Marseille</td>
<td>Tel: 04 91 38 67 34 <a href="mailto:patrick.collignon@ch-toulon.fr">patrick.collignon@ch-toulon.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rennes</td>
<td>Prof Sylvie Odent</td>
<td>Hôpital Sud, 16 boulevard de Bulgarie, BP 90347, 35203 Rennes</td>
<td>Tel: 02 99 26 67 44 <a href="mailto:sylvie.odent@chu-rennes.fr">sylvie.odent@chu-rennes.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toulouse</td>
<td>Dr Yves Dulac</td>
<td>Hôpital des enfants, 330 avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex</td>
<td>Tel: 05 34 55 85 55 edouard.t@chu-toulouse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bordeaux</td>
<td>Dr Marie-Ange Delrue</td>
<td>Hôpital Pellegrin enfants, Place Amélie Rabé Léon, 33076 Bordeaux cedex</td>
<td>Tel: 05 56 79 61 31 <a href="mailto:marie-ange.delrue@chu-bordeaux.fr">marie-ange.delrue@chu-bordeaux.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nancy</td>
<td>Prof Bruno Leheup</td>
<td>CHU Nancy, Hôpital d'enfants, 54500 Vandœuvre les Nancy</td>
<td>Tel: 03 83 15 45 00 <a href="mailto:b.leheup@chu-nancy.fr">b.leheup@chu-nancy.fr</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix V – Reporting incidents or adverse events related to ART to the Agence de la biomédecine

Doctors involved in questions of fertility and human reproduction (gynaecologists-obstetricians, endocrinologists, medical laboratory technologists) are under obligation to report immediately (see part A) or after its conclusion (see part B) an incident or adverse event related to or likely to be related to procedures concerning gametes, germinal tissue or embryos used in ART. The report is sent in writing to the Agence de la biomédecine by the local correspondent of the health watchdog for ART or by any professional who knows of the occurrence of such an incident or adverse event.

The reporting procedure is detailed in the appendices of the Journal officiel no. 0301 of 27 December 2008 (page 20184, text no. 69, NOR: SJSP0830456A), and below.

PART A: immediate reporting of the incident or adverse event

Institute or body concerned.
Person submitting the report.
Material involved: gametes, germinal tissue or embryos.
Where relevant, the donation identification number.
Details on the person or persons involved in cases of an adverse event.
ART procedures concerned.
Date of the incident or adverse event.
Date the incident or adverse event was observed.
Where relevant, date and place of:
— collection or sampling of gametes or germinal tissue;
— artificial insemination;
— embryo transfer.
Stage at which the incident or adverse event occurred.
Description of the event:
— type of incident or adverse event according to the Agence de la biomédecine classification;
— seriousness of the incident or adverse event according to the Agence de la biomédecine classification;
— details of the incident or adverse event;
— flaw in gametes, germinal tissue, embryos;
— defective equipment;
— human error;
— other.
Consequences of the incident or adverse event.
Preventive or corrective measures implemented, including a procedure to stop use of gametes, germinal tissue or embryos.
Has another health watchdog also been informed?

PART B: reporting after conclusion of the incident or adverse event

Confirmation of the incident or adverse event and date of confirmation.
Reclassification of type, if necessary.
Reclassification of seriousness, if necessary.
Preventive or corrective measures implemented.
Clinical outcome, where necessary.
Control of the incident or adverse event.
Avoidability of the incident or adverse event.
Description of the cause of the incident or adverse event.
Results of the investigation and final conclusion.
Appendix VI – Turner Syndrome Registry reporting form

Email to the following address: crmerc.turner@rdb.aphp.fr

<table>
<thead>
<tr>
<th>Name:</th>
<th>Cardiac monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>First name:</td>
<td>(Turner syndrome)</td>
</tr>
<tr>
<td>Date of birth:</td>
<td></td>
</tr>
<tr>
<td>(label)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of evaluation:</th>
<th>Cardiologist: Dr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight (kg):</th>
<th>Blood pressure (mmHg):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Height (cm):</th>
<th>Body surface area (m²):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antihypertensive treatment:</th>
<th>□ NO □ YES</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Electrocardiogram:</th>
<th>normal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>abnormal, specify: □ prolonged QT interval □ other: ........................................</td>
</tr>
</tbody>
</table>

**Known history before the last imaging examination:**

- Cardiovascular surgery □ NO □ YES Indicate type:............... Date: .................
- Hypertension □ NO □ YES
- Bicuspid aortic valve □ NO □ YES □ Undetermined
- Coarctation of the aorta □ NO □ YES Maximum gradient: ......mmHg
- Aortic regurgitation □ NO □ YES
- Aortic valve stenosis □ NO □ YES
- Mitral regurgitation □ NO □ YES
- Mitral valve stenosis □ NO □ YES
- Malformation □ NO □ YES □ Undetermined Specify: .........................

**Results of the last imaging examination:**

- □ Ultrasound of the heart / aorta: Date of last exam: / / 
- □ Magnetic resonance imaging of the heart / aorta: Date of last exam: / / 
- □ Computed tomography of the heart / aorta: Date of last exam: / / 

**IMAGING 1: ULTRASONOGRAPHY**

<table>
<thead>
<tr>
<th>AORTA</th>
<th>Measurement (mm)</th>
<th>AORTA</th>
<th>Measurement (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Aortic annulus</td>
<td>Arch</td>
<td>2-Sinus of Valsalva</td>
<td>Proximal descending</td>
</tr>
<tr>
<td>2-Sinus of Valsalva</td>
<td></td>
<td>3-Sinotubular junction</td>
<td>Thoracic descending</td>
</tr>
<tr>
<td>3-Sinotubular junction</td>
<td></td>
<td>4-Ascending aorta 1 cm from the sinus of Valsalva</td>
<td>Abdominal</td>
</tr>
</tbody>
</table>

Measurements done according to the recommendations of the American Society of Cardiology (leading edge to leading edge, including the anterior wall and excluding the posterior wall). Left parasternal long-axis view (perpendicular to the long axis of the aorta, at end-diastole, averaging over at least 3 cycles).
<table>
<thead>
<tr>
<th>AORTA</th>
<th>Measurement (mm)</th>
<th>AORTA</th>
<th>Measurement (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Aortic annulus</td>
<td>Arch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Sinus of Valsalva</td>
<td>Proximal descending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-Sinotubular junction</td>
<td>Thoracic descending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Ascending aorta 1 cm from the sinuses of Valsalva</td>
<td>Abdominal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cardiac and aortic abnormalities found at last imaging examination:

<table>
<thead>
<tr>
<th></th>
<th>NO</th>
<th>YES</th>
<th>Undetermined</th>
</tr>
</thead>
<tbody>
<tr>
<td>. Bicuspid aortic valve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Coarctation of the aorta</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Aortic regurgitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Aortic valve stenosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average gradient:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Mitral regurgitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Mitral valve stenosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Left ventricular hypertrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Left ventricular end-diastolic volume:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Left ventricular end-systolic volume:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Left ventricular fractional shortening (%):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>. Malformation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cardiologist’s conclusions:

Management:

Next cardiovascular consultation should be scheduled in .................................................................

Next cardiovascular imaging should be scheduled in .................................................................

and should involve: □ ultrasonography □ magnetic resonance imaging of the aorta

Need for perioperative antibiotic prophylaxis for high-risk valve disease □ NO □ YES
APPENDICES:

More frequent cardiological examinations if the largest diameter of the ascending aorta is:
- 2 cm/m² (magnetic resonance imaging: Matura LN. Circulation 2007)
- or 2.1 cm/m² (ultrasonography: Roman MJ. Am J Cardiol 1989)

Seek specialised surgical advice if the largest diameter of the ascending aorta is > 2.5 cm/m²

Calculation of the body surface area according to Dubois (Matura LN. Circulation 2007;116:1663):

Surface area = 0.007184 x height (cm) to the power 0.725 x weight (kg) to the power 0.425

Surface area (m²) - height (cm) - weight (kg)

or simplified if < 30 kg (paediatrics):
Surface area = (4 x weight + 7) / (weight + 90)

Monitoring of aortic diameters:

<table>
<thead>
<tr>
<th>AORTA (mm)/Date</th>
<th>2008</th>
<th>20..</th>
<th>20..</th>
<th>20..</th>
<th>20..</th>
<th>20..</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Aortic annulus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Sinus of Valsalva</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-Sinotubular junction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Ascending aorta at 1 cm from the sinus of Valsalva</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinus of Valsalva/body surface area and/or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinus of Valsalva (DS???)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Morphologie basée sur la coupe parasternale petit axe

**Raphé visualisé**

- OUI «pseudo bicuspid »
  - Raphé = 1
- NON «vraiment bicuspid »
  - Raphé = 2

Fusion: Droite-Gauche

Fusion: Droite-NC

Fusion: Gauche-NC

Cocher la case correspondante
Morphologie basée sur la coupe parasternale petit axe = Morphology based on parasternal short-axis view
Raphé visualisé = Raphe visualised
OUI “pseudo bicuspide” = YES “pseudo bicuspid valve”
NON “vraiment bicuspide” = NO “true bicuspid valve”
Raphé = Raphe
Fusion: Droite-Gauche = Fusion: Right-Left
Fusion: Droite-NC = Fusion: Right-???
Gauche-Droite = Left-Right
Antero-Postérieur = Anteroposterior
Cocher la case correspondante = Tick the appropriate box
Aortic root dimensions/body surface area in normal children and adults (Roman et al. 1989)
# Appendix VII – Accredited egg donation centres

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Telephone</th>
<th>Email</th>
<th>Website</th>
</tr>
</thead>
</table>
| CH des Quatre Villes  
Site de Sèvres | 141 grande rue  
92310 Sèvres | 01 41 14 75 50  
01 41 14 75 24 | martine.lescombes@chi-sevres.fr | www.chi-sevres.fr |
| CHI de Poissy-St Germain en Laye | 10 rue du Champ Gaillard  
78303 Poissy | 01 39 27 51 55 | ampcyto-poissy@hotmail.com | www.chi-poissy-st-germain.fr |
| CHRU de Lille  
Hôpital Jeanne de Flandre  
Gynécologie endocrinienne et médecine de la reproduction | 2 avenue Oscar Lambret  
59037 Lille | 03 20 44 68 97 | c-valdes@chru-lille.fr  
b-drygierczyk@chru-lille.fr | www.chru-lille.fr |
| CHRU de Rennes  
Hôpital sud  
Département d'obstétrique, gynécologie et médecine de la reproduction | 16 boulevard de Bulgarie  
| CHRU de Tours  
Hôpital Bretonneau | 2 boulevard Tonnelle  
37044 Tours | | | www.chu-tours.fr |
| CHU d’Amiens  
Centre de gynécologie obstétrique | 124 rue Camille Desmoulins  
80054 Amiens | 03 22 53 36 75/77 | cecos@chu-amiens.fr | www.chu-amiens.fr |
| CHU de Besançon  
Hôpital St Jacques | 2 place Saint Jacques  
25030 Besançon | 03 81 21 88 04 | fiv@chu-besancon.fr | www.chu-besancon.fr |
| CHU de Clermont-Ferrand  
Hôtel Dieu | 13 boulevard Charles de Gaulle  
63058 Clermont-Ferrand | 04 73 75 01 15 | reproduction@chu-clermontferrand.fr | www.chu-clermontferrand.fr/reproduction |
| CHU de Montpellier  
Hôpital Arnaud de Villeneuve  
Département de médecine et biologie de la reproduction  
Unité d'AMP clinique | 371 avenue du Doyen Giraud  
34295 Montpellier | 04 67 33 64 81 | gyneco-obst-pma@chu-montpellier.fr | www.chu-montpellier.fr |
| CHU de Nice  
Hôpital de l’Arche II | 151 route St Antoine Ginetiere  
06202 Nice | 04 92 03 64 03 | | www.chu-nice.fr |
| CHU de Reims  
Hôpital Maison Blanche | 45 rue Cognacq Jay  
51092 Reims | 03 26 78 77 50 | | www.chu-reims.fr |
| CHU de Toulouse  
Hôpital Pauls de Viguier | 330 avenue de Grande-Bretagne  
31059 Toulouse | 05 67 77 10 05 | | www.chu-toulouse.fr |
| CHU Pellegrin  
Centre clinic d'AMP  
Clinic mutualiste la Sagesse  
Complexe hospitalier du Bocage  
Clinique St Jean Languedoc (Iffrears) | Place Amélie Raba Léon  
33076 Bordeaux  
4 place Saint Guénolé  
35000 Rennes  
20 route de Revel  
31077 Toulouse | 05 56 79 60 33  
02 99 85 75 20  
05 61 54 90 40 | | www.chu-bordeaux.fr  
prat-laurent@wanadoo.fr  
Jerome.degoy@wanadoo.fr |
| Groupe hospitalier du Havre  
Hôpital Jacques Monod  
Hôpital Antoine Béclère  
Service de gynécologie obstétrique médecine de la reproduction  
Hôpital Cochin  
Hôpital de la Conception  
Hôpital Jean Verdier  
Service médecine de la reproduction  
Hôpital St Vincent de Paul | Avenue Pierre Mendes France  
76290 Montvilliers  
157 rue de la Porte de Trivaux  
92140 Clamart  
27 rue du Faubourg St Jacques  
75014 Paris  
147 boulevard Baille  
13005 Marseille  
Avenue du 14 juillet  
93143 Bondy  
82 avenue Denfert Rochereau  
75014 Paris | 02 32 73 33 35  
01 58 41 15 38  
01 48 02 68 56  
01 40 48 81 44 | sec.amp@ch-havre.fr  
amp@chu-dijon.fr  
secmed.sec-amp@jvr.aphp.fr  
f.martinet@svp.aphp.fr | www.aphp.fr  
www.chu-dijon.fr  
www.aphp.fr  
www.aphp.fr |
| Hôpital Tenon  
Service de gynécologie obstétrique et médecine de la reproduction  
Secteur AMP clinique | 4 rue de la Chine  
75970 Paris | 01 56 01 68 69  
(morning) |
|---|---|---|
| Hôpital femme-mère-enfant  
Médecine de la reproduction | 59 boulevard Pinel  
69677 Bron | 04 72 12 94 05  
Sperm donation:  
04 72 11 66 66 |
| Institut mutualiste Montsouris | 42 boulevard Jourdan  
75674 Paris | 01 56 61 61 05/06  
Fax: 01 56 61 66 51 |
| SIHCUS - CMCO | 19 rue Louis Pasteur  
67303 Shiltigheim | 03 88 62 83 13  
martine.camaeti@sihcus.fr |
| Syndicat inter-hospitalier femme-mère-enfant  
Site Sainte Croix | 1-5 place Sainte Croix  
57045 Metz | 03 87 34 51 92 |